• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    NovaBay Pharmaceuticals Announces Name Change to Stablecoin Development Corporation, Reports Initial Staking Rewards, and Provides SKY Token Holdings Update

    3/23/26 8:30:00 AM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NBY alert in real time by email

    Following $134 million investment from R01 Fund LP, Framework Ventures, Tether Investments, S.A. de C.V., and Sky Frontier Foundation, Stablecoin Development Corporation has acquired 2.06 billion SKY tokens

    Key Highlights:

    • Corporate name change from NovaBay Pharmaceuticals, Inc. to Stablecoin Development Corporation; ticker symbol change from NBY to SDEV on the NYSE American, expected to be effective on Friday, April 3, 2026
    • Approximately 2.06 billion SKY tokens held as of March 16, 2026, representing approximately 8.78% of the total supply of SKY
    • Approximately 26.6 million SKY tokens earned in cumulative staking rewards since commencing on-chain staking activities
    • Approximately 1.09 billion SKY tokens acquired on the open market at an average purchase price of approximately $0.065 per SKY token



    EMERYVILLE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE:NBY) (to be renamed Stablecoin Development Corporation (NYSE American: SDEV)) ("NovaBay," "SDEV," or the "Company") today announced that it will change its name to Stablecoin Development Corporation and its NYSE American ticker symbol to SDEV. The Company also provided an update on its previously disclosed strategic investment transaction, on-chain holding company strategy, and initial staking rewards.

    "We are building the premier public market vehicle to access cash flows within the growing stablecoin economy," said Michael Kazley, Chief Executive Officer of SDEV. "The name change to Stablecoin Development Corporation reflects our conviction that stablecoins represent the most compelling structural opportunity in digital finance. With over 2 billion SKY tokens and an active staking program generating protocol-level rewards, we are positioning SDEV at the center of this rapidly evolving ecosystem."

    Private Placement Overview

    As reported in the Company's SEC filings, on January 16, 2026, SDEV entered into a Securities Purchase Agreement with R01 Fund LP, Framework Ventures L.P., Tether Investments, S.A. de C.V., and Sky Frontier Foundation (collectively, the "Purchasers"). Pursuant to the agreement, SDEV issued pre-funded warrants to purchase an aggregate of 167,539,226 shares of its common stock (as adjusted for the 1-for-5 reverse stock split effected on February 23, 2026), resulting in gross proceeds of approximately $134 million (the "January 2026 Private Placement"). The Company has continued to deploy capital toward the acquisition of additional SKY tokens on the open market.

    The private placement financing was accompanied by a broader strategic realignment under which SDEV adopted an on-chain holding company framework focused on long-duration participation in protocol-level digital asset ecosystems, subject to robust governance and risk management oversight.

    Staking Rewards and Additional SKY Acquisitions

    As of March 16, 2026, the Company has earned approximately 26.6 million SKY tokens in cumulative staking rewards since commencing on-chain staking activities. The majority of the Company's SKY holdings are currently deployed in the Sky protocol's staking program. Staking rewards are determined by protocol governance parameters, the level of overall participation in the staking program, and other factors, and are subject to variability over time.

    As part of the January 2026 Private Placement, the Company received approximately 943,599,689 SKY tokens (valued at approximately $58.0 million) as a component of the transaction consideration, in addition to $25.0 million in cash, $51.0 million in stablecoins. Since the closing of the private placement, SDEV has acquired approximately 1.09 billion additional SKY tokens on the open market using $70.7 million of proceeds from the January 2026 Private Placement, at an average purchase price of approximately $0.065 per SKY token. As of March 16, 2026, the Company holds approximately 2.06 billion SKY tokens, representing approximately 8.78% of the total supply of SKY. All SKY tokens acquired by the Company outside of the January 2026 Private Placement have been purchased as freely tradable tokens through open-market transactions, consistent with the Company's digital asset policies.

    Structure Designed for Long-Duration Alignment and Orderly Market Profile

    The warrants issued in the January 2026 Private Placement become exercisable in sequential tranches over an extended period, resulting in a weighted-average delay of approximately 9.9 months before all underlying shares could become eligible for issuance. This tiered structure is intended to support an orderly market profile as the Company executes its strategy.

    In addition, the Securities Purchase Agreement includes post-issuance trading covenants designed to promote stable market dynamics. Following any exercise of a warrant tranche, each Purchaser's aggregate daily sales (together with affiliates) are capped at 10% of SDEV's 30-day average daily trading volume. These volume limitations apply uniformly across all Purchasers, such that every share issued in the transaction is subject to the same post-issuance framework. The Company believes this structure reflects a shared orientation toward long-term alignment rather than short-duration liquidity objectives.

    On-Chain Holding Company Framework

    SKY, the native token of the Sky protocol ecosystem, is currently the only digital asset approved under SDEV's operating and risk management framework. Following its strategic realignment in early 2026, the Company adopted a multi-year capital allocation strategy designed to operate within an on-chain holding company model. Under this framework, SDEV may hold protocol-aligned digital assets for extended periods in order to participate in protocol-level economic activity, while retaining the flexibility to monetize holdings from time to time for general corporate purposes, including liquidity management and tax planning, subject to applicable law and governance oversight. This framework enables the Company to seek long-term economic participation in emerging decentralized networks, subject to prudent risk management and board-level governance controls.

    Stablecoins Context and Institutional Participation

    SDEV views stablecoins as an increasingly important component of global digital financial infrastructure, with expanding use cases across settlement, payments, yield generation, and on-chain capital markets amid evolving regulatory frameworks in the United States and internationally. SDEV is particularly interested in the rise of yield-bearing stablecoins, which generate returns by deploying underlying reserves across diversified strategies spanning real-world asset allocations, on-chain lending, and protocol-native revenue streams. These instruments represent a compelling evolution in digital finance, functioning as productive financial assets that unlock new primitives for savings, treasury management, and capital formation.

    Additionally, the participation of Tether Investments, S.A. de C.V., an affiliate of the issuer of USDT, in the January 2026 Private Placement reflects notable institutional engagement within the broader stablecoin and digital asset ecosystem. The Company believes this participation underscores growing institutional interest in stablecoin-enabled financial infrastructure and related protocol ecosystems.

    On-Chain Participation and Protocol-Published Rewards

    SDEV engages in SKY-related on-chain activities, including staking within the Sky protocol. As disclosed above, these activities have generated approximately 26.6 million SKY tokens in cumulative staking rewards as of March 16, 2026. Such activities are conducted within established risk management parameters and may change over time based on market conditions, protocol governance decisions, and regulatory considerations.

    Certain Sky protocol interfaces publish estimated annualized staking reward rates for SKY. These figures are variable, subject to change, and determined by a combination of protocol governance parameters and the market price of SKY at the time of calculation. Published rates are provided for informational purposes only and do not represent guaranteed yields, returns, or income streams for SDEV or any other participant. Actual results may differ materially.

    About the Sky Protocol

    Sky Protocol is a decentralized finance platform that evolved from MakerDAO, one of the earliest and most established projects in the digital asset ecosystem. The protocol enables the creation and use of USDS, a decentralized stablecoin pegged to the U.S. dollar, and serves as foundational financial infrastructure for lending, savings, and on-chain capital markets. SKY is the governance token of the Sky protocol ecosystem; holders participate in protocol governance through an open, transparent on-chain voting process. The protocol generates revenue from borrowing fees and other economic activity, which is used to fund open-market buybacks of SKY tokens that are then distributed to stakers. SKY has a fixed total supply of approximately 23.46 billion tokens. For more information, visit info.skyeco.com.

    Corporate Name Change

    The Company has approved a change of its corporate name from NovaBay Pharmaceuticals, Inc. to Stablecoin Development Corporation, reflecting the Company's strategic realignment as an on-chain holding company focused on protocol-aligned digital assets within the Sky protocol ecosystem. In connection with the name change, the Company's common stock is expected to begin trading on the NYSE American under the new ticker symbol "SDEV" on Friday, April 3, 2026. The name change does not affect the Company's corporate structure, outstanding shares, or the rights of its stockholders.

    Channels for Disclosure of Information

    Going forward, the Company intends to announce material information to the public through filings with the Securities and Exchange Commission (the "SEC"), the investor relations page on its website, press releases, public conference calls, public webcasts, its X (Twitter) account, and its LinkedIn page. The information disclosed in the foregoing channels could be deemed to be material information. As such, the Company encourages investors, the media, and others to follow the channels listed above and to review the information disclosed through such channels. Investors are always encouraged to refer to SDEV's filings with the Securities and Exchange Commission for additional information.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the Company's strategy; the Company's anticipated name change and ticker symbol change; the expected timing of the commencement of trading under the new name and ticker symbol; the Company's capital allocation strategy; the Company's plans to hold, stake, and potentially monetize SKY tokens and other digital assets; the Company's views regarding the growth and development of the stablecoin economy and related digital asset infrastructure; the variability of staking rewards and protocol governance parameters; and the Company's intentions regarding future SKY token acquisitions. These forward-looking statements are based on management's current expectations and involve known and unknown risks and uncertainties, including risks related to the volatility of digital asset markets, regulatory developments affecting digital assets and staking activities, changes in protocol governance parameters, cybersecurity risks, and other risks and uncertainties described in the Company's most recent Annual Report on Form 10-K filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in the Company's subsequent filings with the SEC. The forward-looking statements in this press release represent management's views as of the date hereof. Actual results may differ materially from those expressed or implied in any forward-looking statements. SDEV undertakes no obligation to update forward-looking statements except as required by law.

    About Stablecoin Development Corporation (currently NovaBay Pharmaceuticals, Inc.)

    Stablecoin Development Corporation (NYSE:SDEV), currently operating as NovaBay Pharmaceuticals, Inc. (NYSE:NBY), is an on-chain holding company focused on long-duration participation in protocol-aligned digital asset ecosystems. The Company's initial digital asset focus is the Sky protocol ecosystem, with SKY as its core holding. Through staking and other on-chain activities, the Company seeks to generate protocol-level economic returns while maintaining rigorous governance and risk management oversight. The Company has announced that it will change its name to Stablecoin Development Corporation and its ticker symbol to SDEV, with trading under the new name expected to commence on Friday, April 3, 2026. Headquartered in Emeryville, California, the Company is committed to prudent governance, regulatory compliance, and long-term shareholder value creation. For more information, please visit www.novabay.com.

    Stay Informed on SDEV's Progress

    Follow us on X (Twitter)

    Connect with us on LinkedIn

    Visit our Website

    Company Contact:

    Tommy Law

    Chief Financial Officer

    [email protected]



    Get the next $NBY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NBY

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NBY
    SEC Filings

    View All

    NovaBay Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)

    3/23/26 8:37:01 AM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by NovaBay Pharmaceuticals Inc.

    10-K - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)

    3/19/26 5:00:41 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NovaBay Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)

    3/12/26 5:19:10 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Poplar Point Capital Partners Lp bought $15,967 worth of shares (28,731 units at $0.56) (SEC Form 4)

    4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

    4/15/25 12:50:08 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Poplar Point Capital Partners Lp bought $74,519 worth of shares (123,365 units at $0.60) (SEC Form 4)

    4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

    4/15/25 12:46:27 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Poplar Point Capital Partners Lp bought $30,718 worth of shares (49,927 units at $0.62) (SEC Form 4)

    4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

    4/15/25 12:40:59 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NovaBay Pharmaceuticals Announces Name Change to Stablecoin Development Corporation, Reports Initial Staking Rewards, and Provides SKY Token Holdings Update

    Following $134 million investment from R01 Fund LP, Framework Ventures, Tether Investments, S.A. de C.V., and Sky Frontier Foundation, Stablecoin Development Corporation has acquired 2.06 billion SKY tokens Key Highlights: Corporate name change from NovaBay Pharmaceuticals, Inc. to Stablecoin Development Corporation; ticker symbol change from NBY to SDEV on the NYSE American, expected to be effective on Friday, April 3, 2026Approximately 2.06 billion SKY tokens held as of March 16, 2026, representing approximately 8.78% of the total supply of SKYApproximately 26.6 million SKY tokens earned in cumulative staking rewards since commencing on-chain staking activitiesApproximately 1.09 billion

    3/23/26 8:30:00 AM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NovaBay Pharmaceuticals, Inc. Regains Compliance with NYSE American Continued Listing Standards

    EMERYVILLE, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces that it has regained compliance with the NYSE American's continued listing standards. As previously disclosed, the NYSE American notified the Company on April 18, 2024 and May 28, 2024 that it was not in compliance with the continued listing standards of the NYSE American Company Guide. Specifically, the notifications indicated that the Company was not in compliance with Sections 1003(a)(i), 1003(a)(ii) and 1003(a)(iii) of the Company guide, requiring a listed company to have stockholders' equity of at least $6 million. Following the issuance and sale of p

    10/20/25 7:07:28 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NovaBay Pharmaceuticals Issues a Reminder of Important Information Regarding the Pending Special Dividend and Upcoming 2025 Annual Meeting

    EMERYVILLE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) (the "Company") previously announced a one-time special cash dividend of $0.80 per share for the Company's common stock. The special cash dividend will be payable on September 29, 2025 to stockholders of record as of the close of business on September 15, 2025. Because the payment of the special dividend represents more than 25% of the price of the Company's common stock, NYSE American advised the Company that its common stock will trade with "due bills" representing an assignment of the right to receive the special dividend from the record date of September 15, 2025 through the close of tradi

    9/18/25 4:30:00 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Lazar David E. was granted 6,388,000 shares (SEC Form 4)

    4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

    1/29/26 7:30:12 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Framework Ventures Iv L.P. converted options into 56,806,080 shares (SEC Form 4)

    4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

    11/3/25 9:39:23 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner R01 Fund Lp converted options into 56,806,080 shares (SEC Form 4)

    4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

    11/3/25 9:38:56 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBY
    Financials

    Live finance-specific insights

    View All

    NovaBay Pharmaceuticals Announces One-Time Special Cash Dividend of $0.80 Per Share

    EMERYVILLE, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces its Board of Directors and the Special Transaction Committee of the Board of Directors has declared a one-time special cash dividend of $0.80 per share of common stock. The special cash dividend will be payable on September 29, 2025 to stockholders of record as of the close of business on September 15, 2025. "This special dividend reflects our commitment to creating and returning value directly to our stockholders," said David Lazar, CEO of NovaBay. "I'm excited about the Company's future as we explore several interesting strategic alternatives." Because

    8/26/25 4:05:00 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NovaBay Pharmaceuticals Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

    EMERYVILLE, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces it has entered into a $6 million securities purchase agreement with private investor David E. Lazar for the purchase of the Company's non-voting convertible preferred stock. NovaBay has received $3.85 million in the first of two closings under the agreement. Effective immediately, Mr. Lazar has been appointed NovaBay's Chief Executive Officer and a director of the Company. Former Chief Executive Officer Justin Hall has assumed the newly created position of Vice President of Business Development. At NovaBay's Special Meeting on April 16, 2025, stockholders

    8/19/25 5:25:32 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NovaBay Pharmaceuticals to Hold Second Quarter 2024 Conference Call on August 13, 2024

    NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces that it will report financial results for the three and six months ended June 30, 2024 after market close on Tuesday, August 13, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time: Tuesday, August 13, 4:30 p.m. ET / 1:30 p.m. PT   Pre-Registration: Participants can pre-register for the conference call here:   Callers who pre-register will be emailed conference details and unique Registration ID to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and

    8/1/24 6:50:00 AM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBY
    Leadership Updates

    Live Leadership Updates

    View All

    NovaBay Pharmaceuticals Issues a Reminder of Important Information Regarding the Pending Special Dividend and Upcoming 2025 Annual Meeting

    EMERYVILLE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) (the "Company") previously announced a one-time special cash dividend of $0.80 per share for the Company's common stock. The special cash dividend will be payable on September 29, 2025 to stockholders of record as of the close of business on September 15, 2025. Because the payment of the special dividend represents more than 25% of the price of the Company's common stock, NYSE American advised the Company that its common stock will trade with "due bills" representing an assignment of the right to receive the special dividend from the record date of September 15, 2025 through the close of tradi

    9/18/25 4:30:00 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Innovations in Disinfection Technology Aid the Return of Workers

    NEW YORK, Dec. 9, 2020 /PRNewswire/ -- The current pandemic has been devastating for the global economy and has caused severe backlogs in hospitals. Additionally, a spike in demand for Personal Protective Equipment (PPE) and new disinfecting technologies has also been seen. For example, when it comes for PPE, the global market was valued at USD 52.7 Billion in 2019 and is expected to reach USD 92.5 Billion by 2025 while growing at a CAGR of 8.7% during 2020-2025, according to VynZ Research. As for new technologies for disinfection, a recent example comes from LG Electronics, which announced on Wednesday the launch of a disinfection robot that will assist in containing the spread of the vi

    12/9/20 9:00:00 AM ET
    $NBY
    $CEMI
    $BSGM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    $NBY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NovaBay Pharmaceuticals Inc.

    SC 13G/A - NovaBay Pharmaceuticals, Inc. (0001389545) (Subject)

    11/8/24 5:31:40 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by NovaBay Pharmaceuticals Inc. (Amendment)

    SC 13G/A - NovaBay Pharmaceuticals, Inc. (0001389545) (Subject)

    2/14/24 2:52:33 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by NovaBay Pharmaceuticals Inc. (Amendment)

    SC 13G/A - NovaBay Pharmaceuticals, Inc. (0001389545) (Subject)

    2/13/24 5:17:39 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care